**InnoCyto Inc.**
15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618

# Technical Data Sheet

PE conjugated Human OX40 (C-His)

**Catalog Number:** 818001, 818002
**Size:** 25 ug, 100 ug
**Target Name:** TNFRSF4, OX40, CD134, OX40L receptor
**Regulatory Status:** RUO

## Product Details

**Application:** FC
**Format:** Liquid, PE
**Expression Host:** CHO
**Species:** Human
**Sources:** Recombinant Human OX40 (Lue29-Ala216) with C-terminus His-tag is expressed in CHO cell and conjugated to PE.
**Accession Number:** P43489
**Molecular Weight:** The protein has a predicted molecular weight of 21.7 kDa. Under DTT-reducing conditions, it migrates at approximately 40 kDa on SDS-PAGE prior to conjugation.
**Affinity Tag:** C-His
**Formulation:** 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
**Endotoxin level:** Not tested
**Protein Concentration:** 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.
**Storage and Handling:** Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

## Background Information

OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.